Induct AS (OSL:INDCT)
1.950
-0.830 (-29.86%)
At close: May 13, 2026
Induct AS Earnings Call Transcripts
Fiscal Year 2025
-
Significant cost reductions and a strategic focus on core healthcare solutions have positioned the company for operational cash positivity in 2025. The collaboration with AstraZeneca and Portsmouth targets rapid scaling of a high-margin asthma care pathway, with strong clinical and financial potential.